Home News Drug Discovery & Development

Drug Discovery & Development

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd. has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval...

Bharat Biotech and University of Maryland Accelerate Development of New Life Saving Conjugate Vaccine...

Receive USD 4 Million Award from The Wellcome Trust for Development and Clinical Trials Hyderabad, India, June 18, 2012: Bharat Biotech and The University of Maryland Center for  Vaccine Development (“CVD”) announced today a significant milestone achievement– receiving a USD  4 Million Strategic Translation Award from The Wellcome Trust for clinical development of a new  conjugate vaccine including initial clinical trials beginning in three years to prevent the potentially  lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS).   NTS have emerged as an important cause of invasive bloodstream infection in sub-Saharan Africa,  among young children with malaria and malnutrition, and among adults with HIV. Strains of nontyphoidal Salmonella (“NTS”) that can cause systemic disease such as meningitis or sepsis are  particularly common in sub-Saharan Africa; approximately 20 to 30% of children with such invasive  NTS infections die.

Panav Bio-Tech Introduces Classical Swine Fever – Himmvac Hog Cholera (T/C) Vaccine in India

New Delhi, December 06, 2018: Panav Bio-Tech, a leading company in the animal healthcare, is now offering a vaccine for classical swine fever or Hog Cholera in India. Panav Bio-Tech has a diverse portfolio of Bio-preparation that consists of vaccines that...

Cadila Healthcare divests its entire stake in Bremer Pharma, Germany

Mumbai, April 20, 2018: Cadila Healthcare said that company has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company. The company received...

France Telemedicine Outlook to 2022: Ken Research

New Delhi, November 17, 2018: The report titled “France Telemedicine Outlook to 2022- By Services and Technology, By Service Platform (Telehealth & M-Health, Telehospitals & Clinics), By Clinical Applications (Telemonitoring, Teleconsultation, Teleassistance, Teleexpertise and Others)” provides a comprehensive analysis...

AstraZeneca to shut R&D centre in Bangalore

168 research jobs at stake; had during 2012 shed some R&D jobsBangalore January 31, 2014: AstraZeneca, the global pharmaceutical major,  said that it will close its research and development site in Bangalore later this year.  The ‘Avishkar R&D Site’,...

Cipla bets big on cell therapy

Mumbai , March 22,2014 - Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be...

Developments in Bio-informatics will help drive discoveries

    • Training,  revamp  of  University  system,  Promote  Translation  of  Academicre search, Promoting Bio-Entrepreneurship will accelerate the industry growth

 

  • Synthetic  Biotechnology  has  tremendous  potential,  affordable  gene  sequencing can play a major role in the Food, Energy, fragrance & Flavors

Drug Discovery Unit (DDU), University of Dundee Licenses GVK BIO Online SAR Database (GOSTAR)

Hyderabad, Andhra Pradesh, India, Wednesday, April 10, 2013 -- (Business Wire India) -- GVK Biosciences (GVK BIO) today announced that it has licensed its Online SAR Database - GOSTAR to the Drug Discovery Unit (DDU) at the University of Dundee. GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 curators. The product issued globally in various areas such as pharmaceuticals, academics, government sectors, apart from numerous publications that cite the data contained in GOSTAR. GOSTAR contains over 6 million compounds manually curated through the screening of over 2 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.

MedGenome study suggests a personalized cancer vaccine approach to treat Lynch Syndrome

National, September 06, 2018: A breakthrough study on ‘cancer vaccine approach for personalized treatment of Lynch Syndrome’ by MedGenome was published in Scientific Reports this month. The published study in collaboration with Kailash Cancer Hospital and Research Center (KCHRC),...